Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 6/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19912587 | 1.00 | MAPT (0.43) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL23693964 | 0.86 | PHF8 (0.46) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL23694892 | 0.86 | PHF8 (0.46) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL23694900 | 0.86 | PHF8 (0.46) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL402501 | 0.85 | MAPT (0.57) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL406117 | 0.76 | PRKCA (0.63) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL13901278 | 0.73 | MAPT (0.61) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25475240 | 0.73 | ACE (0.38) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL11272747 | 0.73 | MGAM (0.44) | — | |
| SCHEMBL16020408 | 0.72 | ALDH1A1 (0.46) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | MAPT 3747/4885MAPK1 2202/4885PRKCA 4150/4885 |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | MAPT 4313/4885MAPK1 2965/4885PRKCA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.